FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964820176> ?p ?o ?g. }

• W1964820176 endingPage "48" @default.
• W1964820176 startingPage "33" @default.
• W1964820176 abstract "AbstractMost antihyperglycemic agents available for the treatment of type 2 diabetes mellitus (T2DM) have insulin-dependent mechanisms of action; that is, they either stimulate insulin production (sulfonylureas, glinides, incretin mimetics, dipeptidyl peptidase-4 inhibitors), improve insulin sensitivity (thiazolidinediones, biguanides), or directly augment endogenous insulin (basal and prandial insulins). As β-cell function deteriorates, combination therapy is usually needed to effectively control glycemia. Moreover, some antihyperglycemic agents are associated with adverse effects, such as weight gain and hypoglycemia. A novel approach for treating T2DM is to inhibit renal glucose reabsorption through inhibition of sodium glucose co-transporter 2 (SGLT2), which is responsible for the majority of glucose reabsorption in the renal proximal tubule. By reducing the renal capacity to reabsorb filtered glucose, SGLT2 inhibitors increase excretion of excess glucose in urine, thereby decreasing plasma glucose concentration. Thus, although glucosuria is often viewed as an indicator of systemic hyperglycemia, this perception needs to be modified in patients treated with SGLT2 inhibitors where glucosuria is an indicator of the desired treatment effect. Currently, 2 SGLT2 inhibitors, canagliflozin and dapagliflozin, are approved in the United States for the treatment of patients with T2DM; other SGLT2 inhibitors are in various stages of clinical development. Clinical studies in patients with T2DM on a variety of background diabetes treatments have demonstrated the efficacy of canagliflozin and dapagliflozin in improving glycemic control and reducing body weight and blood pressure. Canagliflozin and dapagliflozin are generally well tolerated, with a low risk of hypoglycemia when not used in combination with insulin and/or sulfonylurea. Higher incidences of genital mycotic infections and adverse events related to osmotic diuresis and volume depletion were observed with both agents; they were generally mild or moderate and infrequently led to study discontinuation. Based on current evidence, SGLT2 inhibitors provide an important new treatment option for patients with T2DM.Keywords: type 2 diabetes mellitussodium glucose co-transporter 2 (SGLT2) inhibitorantihyperglycemic agentmechanism of action" @default.
• W1964820176 created "2016-06-24" @default.
• W1964820176 creator A5064627053 @default.
• W1964820176 creator A5081667069 @default.
• W1964820176 date "2014-10-01" @default.
• W1964820176 modified "2023-10-18" @default.
• W1964820176 title "Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes" @default.
• W1964820176 cites W1606165384 @default.
• W1964820176 cites W175419662 @default.
• W1964820176 cites W1967064223 @default.
• W1964820176 cites W1968145432 @default.
• W1964820176 cites W1969550954 @default.
• W1964820176 cites W1973240292 @default.
• W1964820176 cites W1974115114 @default.
• W1964820176 cites W1982368369 @default.
• W1964820176 cites W1987553321 @default.
• W1964820176 cites W1997018189 @default.
• W1964820176 cites W1999892123 @default.
• W1964820176 cites W2008443217 @default.
• W1964820176 cites W2021988691 @default.
• W1964820176 cites W2030192134 @default.
• W1964820176 cites W2038270027 @default.
• W1964820176 cites W2038961968 @default.
• W1964820176 cites W2047553605 @default.
• W1964820176 cites W2051243940 @default.
• W1964820176 cites W2058484049 @default.
• W1964820176 cites W2068171948 @default.
• W1964820176 cites W2069751682 @default.
• W1964820176 cites W2069845056 @default.
• W1964820176 cites W2070579138 @default.
• W1964820176 cites W2074989651 @default.
• W1964820176 cites W2077038286 @default.
• W1964820176 cites W2081510795 @default.
• W1964820176 cites W2084511068 @default.
• W1964820176 cites W2090088543 @default.
• W1964820176 cites W2096329362 @default.
• W1964820176 cites W2101244337 @default.
• W1964820176 cites W2101865653 @default.
• W1964820176 cites W2103196856 @default.
• W1964820176 cites W2105660444 @default.
• W1964820176 cites W2109728760 @default.
• W1964820176 cites W2113551073 @default.
• W1964820176 cites W2114276479 @default.
• W1964820176 cites W2117505171 @default.
• W1964820176 cites W2118613762 @default.
• W1964820176 cites W2120919346 @default.
• W1964820176 cites W2120922908 @default.
• W1964820176 cites W2122077393 @default.
• W1964820176 cites W2123984464 @default.
• W1964820176 cites W2124234371 @default.
• W1964820176 cites W2128219379 @default.
• W1964820176 cites W2130570549 @default.
• W1964820176 cites W2131135469 @default.
• W1964820176 cites W2133469996 @default.
• W1964820176 cites W2135097670 @default.
• W1964820176 cites W2135414357 @default.
• W1964820176 cites W2137467405 @default.
• W1964820176 cites W2141228342 @default.
• W1964820176 cites W2142360957 @default.
• W1964820176 cites W2144213974 @default.
• W1964820176 cites W2149973065 @default.
• W1964820176 cites W2152397610 @default.
• W1964820176 cites W2154020052 @default.
• W1964820176 cites W2155287847 @default.
• W1964820176 cites W2158482469 @default.
• W1964820176 cites W2160471487 @default.
• W1964820176 cites W2162427196 @default.
• W1964820176 cites W2162752164 @default.
• W1964820176 cites W2168926920 @default.
• W1964820176 cites W2169403426 @default.
• W1964820176 cites W2171049608 @default.
• W1964820176 cites W2171471305 @default.
• W1964820176 cites W2172193326 @default.
• W1964820176 cites W4229629337 @default.
• W1964820176 doi "https://doi.org/10.3810/pgm.2014.10.2819" @default.
• W1964820176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25414933" @default.
• W1964820176 hasPublicationYear "2014" @default.
• W1964820176 type Work @default.
• W1964820176 sameAs 1964820176 @default.
• W1964820176 citedByCount "31" @default.
• W1964820176 countsByYear W19648201762015 @default.
• W1964820176 countsByYear W19648201762016 @default.
• W1964820176 countsByYear W19648201762017 @default.
• W1964820176 countsByYear W19648201762018 @default.
• W1964820176 countsByYear W19648201762019 @default.
• W1964820176 countsByYear W19648201762020 @default.
• W1964820176 countsByYear W19648201762021 @default.
• W1964820176 countsByYear W19648201762022 @default.
• W1964820176 countsByYear W19648201762023 @default.
• W1964820176 crossrefType "journal-article" @default.
• W1964820176 hasAuthorship W1964820176A5064627053 @default.
• W1964820176 hasAuthorship W1964820176A5081667069 @default.
• W1964820176 hasConcept C126322002 @default.
• W1964820176 hasConcept C134018914 @default.
• W1964820176 hasConcept C2777180221 @default.
• W1964820176 hasConcept C2777422806 @default.
• W1964820176 hasConcept C2777451236 @default.
• W1964820176 hasConcept C2779306644 @default.

• next